中國神華(01088.HK):預計2021年淨利達516億元 同比增44%
格隆匯1月27日丨中國神華(01088.HK)發佈2021年度業績預吿,經初步測算,預計集團2021年度的歸屬於公司所有者的本年利潤約為人民幣516億元(2020年度:人民幣358.49億元),同比增長約44%。
公吿表示,影響2021年歸屬於公司所有者的本年利潤的主要因素為:(一)增利因素。集團煤炭銷售量和平均銷售價格同比增長,航運貨運量和運價同比增長,以及聚烯烴產品價格同比上漲。(二)減利因素。集團自產煤單位生產成本、外購煤單位採購成本和燃煤電廠單位售電成本同比增長,投資收益同比減少,以及計提減值損失同比增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.